Vascular endothelial growth factor antibody attenuates diabetic peripheral neuropathic pain in rats.
10.11817/j.issn.1672-7347.2018.10.009
- Author:
Bingbing PAN
1
;
Huijuan DING
2
;
Zhigang CHENG
1
;
Zongbin SONG
1
;
Dan XIAO
2
;
Qulian GUO
1
Author Information
1. Department of Anesthesiology, Xiangya hospital, Central South University, Changsha 410008, China.
2. Department of Anesthesiology, Hunan Provincial People's Hospital, Changsha 410005, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Antibodies;
pharmacology;
therapeutic use;
Diabetes Mellitus, Experimental;
chemically induced;
Diabetic Neuropathies;
chemically induced;
drug therapy;
Gene Expression Regulation;
drug effects;
Male;
Phosphatidylinositol 3-Kinases;
Random Allocation;
Rats;
Rats, Sprague-Dawley;
TRPV Cation Channels;
genetics;
Vascular Endothelial Growth Factor A;
metabolism
- From:
Journal of Central South University(Medical Sciences)
2018;43(10):1097-1102
- CountryChina
- Language:Chinese
-
Abstract:
To explore the role of vascular endothelial growth factor (VEGF) in diabetic peripheral neuropathic pain in rats.
Methods: Twenty-four adult male Sprague-Dawley rats aged 8 weeks were randomly divided into 3 groups (n=8 per group). The control group (C group): rats were intraperitoneally injected with sodium citrate solution at 10 mL/kg; the model group (M group): rats were intraperitoneally injected with streptozotocin at 65 mg/kg; the treatment group (T group): rats received intraperitoneal injection of anti-VEGF antibody (10 mg/kg) at the 1st, 3rd, 7th, 10th day after STZ treatment. Meanwhile, rats of C and M group were received with the same volume of sodium citrate solution. Blood glucose was measured before 1 day or at the 1st, 3rd, 7th or 14th day after receiving STZ. Body weight, paw withdrawal mechanical threshold (PWMT) and paw withdrawal thermal latency (PWTL) were measured before 1 day or at the 1st, 3rd, 5th, 7th, 10th or 14th day after receiving STZ. All lumbar spinal cords were dissected to examine the p-protein kinase B (p-Akt) and transient receptor potential vanilloid 1 (TRPV1) expression by Western blot.
Results: After injection with STZ, the body weight showed significant differences at some time point between the M, T or C group (P<0.01); body weight of rat in the C group were increased gradually. Compared with the C group, the fast blood glucose in the M or the T Group at the same time points were increased significantly (P<0.01). The PWMT and PWTL of the M, T or C group were significant difference among various time points (P<0.01). The PWMT and PWTL in the M or T group were obviously reduced compared with those in the C group (P<0.01). Compared with the M group, the PWMT and PWTL in the T group were increased at the 10th or 14th day (P<0.01 or P<0.05). Compared with the C group, the p-Akt and TRPV1 levels in the M and T group were increased (P<0.01). Compared with the M group, p-Akt and TRPV1 levels in T group were decreased (P<0.01).
Conclusion: VEGF is able to regulate the expression of TRPV1 through PI3K/Akt pathway, which contributes to diabetic peripheral neuropathic pain in rats. Anti-VEGF treatment may be useful for alleviation of diabetic peripheral neuropathic pain.
